Reference drugs for triple combination test drug in Russia [Design Issues]

posted by Beholder  – Russia, 2019-11-19 14:39 (379 d 18:11 ago) – Posting: # 20828
Views: 3,030

» We don't know nothing about new FDC - no safety, no efficacy data. This is new drug.

Why no safety and efficacy data!? Lets take abovementioned examples:

Amlodipine + Indapamide + Perindopril - here
Losartan + Amlodipine + Rosuvastatin - here.
Indapamide + Rosuvastatin + Perindopril here.

So, can we say that "In all cases, the established regime has a well-characterized safety and efficacy profile..." and proceed with Scenario 2 comparing triple combination with two reference drugs?!

Best regards

Complete thread:

 Admin contact
21,233 posts in 4,428 threads, 1,482 registered users;
online 5 (1 registered, 4 guests [including 4 identified bots]).
Forum time: Thursday 08:51 CET (Europe/Vienna)

Every man is fully satisfied that there is such a thing as truth,
or he would not ask any question.    Charles Sanders Peirce

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz